GRACE :: Lung Cancer

Search cancerGRACE.org

Dr West

Balloons vs. Puddles: Can We Do Smaller Surgeries after Induction Therapy for NSCLC?

Share
download as a pdf file Download PDF of this page

In my thoracic oncology tumor board today, we discussed a situation that comes up fairly often: a patient has a collapsed lung lobe from a tumor near the middle of the chest, with some regional lymph nodes involved, and the surgeon thinks he’s likely to need the whole lung removed because the location of the tumor is nestled in just the wrong place.  The patient has enough lung function to undergo surgery, but losing an entire lung (pneumonectomy) is a big loss, and he’s already only a debatable candidate to be able to undergo surgery safely.  So the question emerges, “Can we give pre-operative chemotherapy specifically with the intent of shrinking a cancer enough to enable a less extensive surgery than would be needed if no pre-operative therapy is done?”

It’s a question that doesn’t have a clear answer.  The concept of “downstaging” a cancer with neoadjuvant (pre-operative) chemotherapy or chemo/radiation is an appealing potential appeal of the strategy, but there isn’t clear evidence that it really works.  In the ChEST trial that has been recently published that compared pre-operative cisplatin/gemcitabine chemotherapy followed by surgery to surgery alone, the recipients of neoadjuvant therapy were less likely to have undergone a pneumonectomy (17% vs. 25%) and more likely to have received a lobectomy (70% vs. 60%) .  On the other hand, the SouthWest Oncology Group (SWOG) ran a similar neoadjuvant chemotherapy trial and found that there were no differences in the pneumonectomy rates with or without pre-op chemo — 17% in both arms.  What gives?

Part of the challenge is that surgeons have different styles: some have come to believe that a cancer is like a balloon, and if it appears to shrink, you presume that the new borders of the cancer don’t have any additional cancer around them.  Therefore, it’s OK to do a smaller surgery than you would have originally done.  On the other hand, some surgeons see a cancer as a puddle drying up, so that even though the main borders are smaller on repeat scans, and maybe even when directly visualized by the surgeon, you can’t be confident that there aren’t little satellite areas of cancer outside of the main borders.  Therefore, they feel that if someone needed a pneumonectomy originally, you can’t do a smaller surgery after pre-operative therapy, even if it looks as if the cancer is now small enough to enable a more limited surgery.

So the question of which patients receive a larger or smaller surgery depend only in part on what their tumor requires, and in part on the philosophy of the medical team (but usually especially the surgeon, who tends to get more votes in such matters).   We can’t rely on the rates of pneumonectomy vs. lobectomy to tell us whether all of the pneumonectomies were clearly needed or not.  What would be most helpful would be to determine if the patients who were deemed to require a pneumonectomy that was then converted to a lobectomy do just as well as the patients who were anticipated to require a lobectomy from the beginning.  But to my knowledge, we don’t have any such data.

In the end, let me give you a sense of how variable these styles are. I work with four board-certfied, excellent thoracic surgeons who get along amazingly well, even if they don’t all do things the same way. Two of them favor revising the surgery after pre-operative therapy, and two favor doing the original surgery that would have been required.  And the one who presented the case today? He favored pre-operative therapy for a patient we shared a few months ago (but who ended up requiring a pneumonectomy after neoadjuvant chemo/radiation anyway), but for this particular patient, he favored up front surgery with a pneumonectomy.  In the more recent case, he wasn’t at all optimistic that the operative options would be better after chemo or chemo/radiation.  It just goes to show how individualized patients and their cancers can be, with no “right way” for everyone, even with the same surgeon and team.


5 Responses to Balloons vs. Puddles: Can We Do Smaller Surgeries after Induction Therapy for NSCLC?

  • Dr West
    Dr West says:

    Because we are trying to help a community of people, the doctors here just can’t spend so much time to ccarefully review such a long and detailed description of your situation followed by an extensive list of very open ended questions, which are.therefore prohibitively time consuming to answer.

    We would be happy to try to help if you can just provide a much more abbreviated summary of your current situation and pone or two high priority questions that are specific enough for us to answer in a reasonable amount of time. If you want to ask additional questions over time, we can try to help with additional questions. But we need to share our limited time with other people who have their own questions.

    -Dr. West

  • Craig says:

    Dr. West,

    Does this new research abstract shed any light on the balloon hypothesis vs. puddle hypotheses?:
    “Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer,” Lung Cancer, May 2012
    http://www.lungcancerjournal.info/article/PIIS016950021100568X

    I can’t access the full text (not for free), but the abstract makes me think there might be some info there.

    Best hopes,

  • Dr West
    Dr West says:

    No, because it’s looking at residual viable cells within an existing mass. The “balloon vs. puddle” question boils down to whether a cancer can shrink and have its outer portion resorbed by the body but still leave a few stray viable cancer cells present outside of the boundaries of the remaining mass.

    But thanks for the interesting link.

    -Dr. West

  • agent99
    agent99 says:

    Dear Dr. West,
    My intent is to explore any treatment that would preclude my husband’s pneumonectomy but not postpone surgery if the data are inconclusive, nonexistent or lack significant benefit. Pneumonectomy is necessary because tumor appears to straddle the major fissure of rt lung. My questions are:

    1. Is it likely that a course of neoadjuvant therapy could shrink a 35mmx24mm tumor to a size worth considering lobectomy?
    2. Is the darn location of the tumor, no matter how small it could get, simply rule out any benefit?

    We see the surgeon for the first time this afternoon. I will find out if he favors balloons or puddles!

    As always, many thanks,
    Lisa

  • Dr West
    Dr West says:

    The US-based SWOG 9900 study looked specifically at this question and found no difference in the rate of pneumonectomies vs. lobectomy in patients who went straight to surgery vs. had chemotherapy first. Perhaps that’s because many of the surgeons felt that you should do the surgery the patient needed initially. On the other hand, there were fewer patients who underwent pneumonectomy after neoadjuvant chemotherapy In an Italian trial, called ChEST. I can say that at our center, we remain open to the possibility that a person will respond well enough to not require a pneumonectomy after pre-operative therapy, but we can’t presume that will work.

    Yes, sometimes the location of the cancer simply precludes any surgery short of a pneumonectomy. The surgeon would be able to speak to that, as it depends exactly where the cancer actually is.

    Good luck.

    -Dr. West

Leave a Reply

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share
download as a pdf file Download PDF of this page

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share
download as a pdf file Download PDF of this page

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share
download as a pdf file Download PDF of this page

Subscribe to the GRACEcast Podcast on iTunes

Share
download as a pdf file Download PDF of this page

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share
download as a pdf file Download PDF of this page

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243